In vivo characterization plays a pivotal role at various stages of the drug discovery and development process, enabling researchers to gain vital insightsinto the pharmacokinetics, metabolism, and overall behavior of a drug candidate within a living organism. At Admescope, our AAALAC-accredited animal unit is seamlessly integrated with comprehensive bioanalytical laboratories, ensuring efficient study management, streamlined workflows, and fast turnaround times to meet your project goals.
Our service portfolio encompasses a wide range of in vivo capabilities. From rapid PK screenings designed for early-stage evaluations to detailed investigations of pharmacokinetic parameters and in vivo metabolite identification, we provide the data you need to make informed decisions. The protocols can be modified to meet the needs of your project.
To enhance understanding of the complete disposition of a drug and its related materials, we offer rodent mass balance studies utilizing 14C- or 3H-labeled compounds. These studies are instrumental in characterizing the route of excretion, identifying whether the drug is eliminated through urine, feces, bile, or other pathways, and metabolic pathways, providing a detailed understanding of how the drug is processed within the body. In these experiments, animals are housed in specialized metabolic cages, enabling complete collection of excreta alongside plasma sampling during the study, as well as collection of selected tissues post-mortem.
Metabolite identification (MetID) is a key component of these studies and can be performed as part of mass balance experiments or as a stand alone for the in vivo samples. Additionally, we can complement in vivo studies with in vitro metabolite identification, leveraging various metabolic systems to provide a complete picture of drug metabolism, also with radio labelled compounds. Importantly, our in vivo MetID services are not limited to samples generated in our facilities. We can analyze samples from studies conducted elsewhere, ensuring flexibility and continuity in your research efforts.
For drug candidates progressing to later stages of development, we offer specialized services such as metabolite identification for radiolabeled compounds to support detailed analysis of metabolites generated in vivo. Additionally, our safety metabolism studies will support you to evaluate, whether human metabolites are adequately represented in the applied preclinical toxicological species.
With our integrated animal unit and bioanalytical laboratories, commitment to precision, and ability to customize study designs, Admescope provides a comprehensive suite of in vivo and bioanalytical services. Whether you’re seeking rapid PK data, detailed metabolite profiling, or regulatory-compliant safety metabolism studies, our team is here to support you at every step of your journey.
Contact us today to learn how our in vivo capabilities can drive the success of your drug discovery and development projects.
Admescope’ s E-Book series continues:
Preclinical Characterization of Biologics – Part 2
If you didn’t yet do so, we recommend you check out our latest e-book: Preclinical Characterization of Biologics: Part 2.
This e-book focuses on two types of biological drugs: antibody-drug conjugates (ADCs) and oligonucleotides. Both modalities offer unique advantages and present distinct challenges in drug discovery and development. The e-book provides a comprehensive overview of their pharmacokinetics, preclinical ADME characterization, and the analytical techniques commonly used to study them.
Don’t miss this interesting read, download your free copy now from our website!
